Esophageal Squamous Cell Carcinoma — Trials

Esophageal Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 212
Recruiting: 119
Ph III recruiting: 20
Growth YoY: +61.4%
Industry share: 23%
Top sponsor: Fudan University
Termination share: 25%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (35)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04949256	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).	terminated	Phase 3	863	Merck Sharp & Dohme LLCINDUSTRY	25	Aug 21, 2026	clinicaltrials
NCT01627379	Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer(POWER)	terminated	Phase 3	300	AIO-Studien-gGmbHOTHER	1